Herbert Tilg

Plain English
This study looked at the health effects of artificial sweeteners, which are commonly used as sugar substitutes. It found that these sweeteners may make people feel hungrier, leading to eating more calories, gaining weight, and increasing the risk of obesity, type 2 diabetes, and heart disease. Additionally, there are early signs that they might influence cancer growth. Who this helps: Patients concerned about their weight and overall health, as well as healthcare providers guiding dietary choices.

Plain English
This study reviewed metabolic dysfunction-associated steatotic liver disease (MASLD), which includes liver fat buildup and inflammation and affects 30% to 40% of adults worldwide, with even higher rates (60% to 80%) among people with type 2 diabetes and obesity. The research highlighted that MASLD can lead to serious health issues like liver cancer and heart disease, making its management crucial. Treatment mainly focuses on lifestyle changes such as diet and exercise, with two medications, resmetirom and semaglutide, approved for patients with more severe cases. Who this helps: This benefits patients suffering from liver disease, particularly those with obesity and type 2 diabetes.

Plain English
This study looked at a group of proteins called IL-1 cytokines, which play a key role in inflammation affecting the stomach and liver. Researchers found that these cytokines are involved in many diseases of these organs, helping to explain why they often suffer from immune-related problems. Understanding their role can lead to new treatments that target these inflammatory processes. Who this helps: Patients with gastrointestinal and liver disorders.

Plain English
This study investigated specific proteins found in the stools of patients with inflammatory bowel disease (IBD) to better understand their connection to disease activity. Researchers found that stools from patients with active IBD contained higher levels of two protein subunits, S100A8 and S100A9, which were linked to worsening disease symptoms, even when another marker, calprotectin, was low. This is important because it reveals potential new ways to diagnose and treat IBD by focusing on these protein subunits. Who this helps: This helps patients with inflammatory bowel disease and their doctors.

Plain English
Researchers studied how a Western diet, which includes a lot of certain fats, affects the body’s response in patients with Crohn's disease (CD). They found that a specific protein called RXRα became more active in the intestinal cells of people with CD, especially when exposed to certain fats. In mouse experiments, a treatment called isotretinoin helped reduce related inflammation, and looking at health records revealed that this treatment lowered the risk of developing CD for many patients. Who this helps: This benefits patients with Crohn's disease and those at risk for the condition.

Plain English
This study examined how a specific gene, ATG16L1, influences gut inflammation caused by a diet high in fats, similar to Western eating patterns. Researchers found that when mice consumed a diet rich in certain fatty acids, ATG16L1 was key to triggering an inflammatory response in gut cells, leading to symptoms similar to Crohn's disease. Essentially, this research reveals that rather than just protecting the gut, ATG16L1 can also contribute to inflammation, highlighting a complex relationship between diet and gut health. Who this helps: This helps patients with gut diseases, especially those affected by dietary choices.

Plain English
The study examined a protein called interleukin-38 (IL-38) to see how it relates to the severity of advanced fatty liver disease in 184 patients. Researchers found that IL-38 levels were significantly higher in patients with severe symptoms compared to those with milder forms of the disease, with levels increasing by about 9.2% for each point increase in a severity scoring system called MELD. This is important because it suggests that measuring IL-38 could help doctors identify how serious a patient's condition is and guide their treatment more effectively. Who this helps: Patients with advanced fatty liver disease and their doctors.

Plain English
This paper examines how to better manage a liver disease called metabolic dysfunction-associated steatohepatitis (MASH), which affects about 30% of adults, with a significant risk of worsening to serious conditions like cirrhosis or liver cancer. It highlights the connection between MASH and heart disease, noting that current treatments often overlook both organs, leading to higher risks for patients. The research reviews three types of medications: those that target metabolic issues in the body, those that focus on liver diseases, and heart medications that may help protect the liver, stressing that a coordinated care approach is essential for better patient health outcomes. Who this helps: This helps patients with MASH and heart disease.

Plain English
This study looked at different ways to screen for colorectal cancer (CRC) in the general population in Austria, including various tests and their timing. The researchers found that starting colonoscopy screening at age 40 or 50 could save a significant number of lives, gaining 449 life-years for every 1,000 people screened, while an annual fecal immunochemical test (FIT) starting at age 40 resulted in 488 life-years gained per 1,000 individuals. This matters because it helps identify effective screening strategies that can save lives while weighing the risks and costs involved. Who this helps: This benefits patients at risk of colorectal cancer and healthcare providers involved in screening practices.

Plain English
The study looked at common metabolic diseases in the Asia-Pacific region from 1990 to 2023, focusing on issues like high blood pressure, obesity, and diabetes. It found that high blood pressure is the biggest problem, causing about 138 million years of healthy life lost and over 6 million deaths in 2023. These diseases are expected to keep increasing, which highlights the urgent need for coordinated efforts to improve health in these areas. Who this helps: This research benefits patients, healthcare providers, and policymakers working to reduce the impact of these diseases.

Plain English
This study looked at how metabolic dysfunction-associated steatotic liver disease (MASLD) affects the risk of colorectal cancer (CRC), finding that people with MASLD face a higher CRC risk. The researchers gathered input from 35 international medical experts and reached agreement on 17 key points, confirming that the severity of MASLD increases the risk of developing CRC and that lifestyle changes, early screenings, and certain medications could help reduce this risk. This is important because identifying and managing CRC risk in MASLD patients can potentially save lives and improve health outcomes. Who this helps: Patients with MASLD and their healthcare providers.

Plain English
This research studied the effects of two intravenous iron treatments for iron deficiency anemia: ferric carboxymaltose (FCM) and ferric derisomaltose (FDI). It found that patients receiving FCM had a significantly higher risk of bone problems, with a fracture rate that was more frequent than those treated with FDI. Specifically, in a group of 357 patients, those on FCM had a much greater chance of developing osteomalacia (bone softening) and fractures, which was confirmed in a larger analysis of over 20,000 patients. Who this helps: This information is crucial for doctors treating patients with iron deficiency anemia, especially when considering which iron treatment to use.

Plain English
This study examined how changes in a specific protein, called GPX4, in the intestines of patients with Crohn's disease can predict if their condition will worsen after surgery. Researchers found that lower levels of GPX4 were present in patients who experienced a return of their disease, and this was true for 241 patients across multiple groups. By understanding this connection, doctors may be able to better identify who is at risk for recurring symptoms and potentially offer targeted treatments to help manage the disease. Who this helps: This benefits Crohn's disease patients and their doctors.

Plain English
This study looked at a condition called ferroportin disease (FD) and its relationship with another condition called SLC40A1-related hemochromatosis (SLC40A1-HC), both caused by changes in the same gene. Researchers analyzed data from 95 patients with these conditions and found that 65.5% of them had the FD type, which often shows up in younger females and is linked to higher iron levels in the liver and spleen compared to SLC40A1-HC patients. The findings highlight that while most patients receive regular bloodletting treatments (phlebotomies), these treatments don't seem to affect their life expectancy, indicating the need for more personalized treatment approaches. Who this helps: This information benefits patients with iron overload disorders and their doctors.

Plain English
This study looks at how liver inflammation develops in a condition called metabolic dysfunction-associated steatohepatitis (MASH), which affects about 20% of people with liver issues related to fatty liver disease. Researchers found that MASH is driven by various factors, including liver fat buildup, gut health, and poor diets, along with inflammation caused by obesity. Understanding these pathways is crucial because it could lead to new treatments for MASH that not only target liver problems but also address other health issues related to obesity. Who this helps: This benefits patients suffering from liver diseases, especially those with MASH.

Plain English
This paper looks at how metabolic bariatric surgery (MBS) might help patients with cirrhosis caused by a liver condition called MASLD. It highlights that MBS could improve liver function but points out challenges like the need for careful pre-surgery evaluations and the risk of complications afterward. The authors emphasize the importance of more research in this area to fully understand the benefits and risks. Who this helps: This helps patients with MASLD-related cirrhosis who may need better treatment options.

Plain English
This study looked at how metabolic dysfunction-associated steatotic liver disease (MASLD) affects the likelihood of serious bacterial infections that require hospital treatment. The researchers analyzed data from about 26.6 million people and found that those with MASLD were nearly twice as likely (1.93 times) to be admitted for serious infections compared to those without the disease. The risk was even higher for individuals with more severe cases of MASLD, particularly those with advanced fibrosis, showing over two times the risk (2.42 times). Who this helps: This information is important for patients with MASLD and their doctors, as it highlights the need for monitoring and preventive measures against infections.

Plain English
This study looked at new treatments for a liver disease called metabolic dysfunction-associated steatotic liver disease (MASLD) and its more serious form, metabolic dysfunction-associated steatohepatitis (MASH). Researchers found that medicines called incretin receptor agonists, which are already used for type 2 diabetes and obesity, can help improve liver health, with promising results from clinical trials showing improvements in liver tissue and related health issues. This is important because effective treatments for MASLD/MASH are currently lacking, and these new options could significantly help patients with these liver conditions. Who this helps: Patients suffering from MASLD and MASH, especially those with obesity or type 2 diabetes.

Plain English
This study looked at the outcomes of liver transplants (LT) using normothermic liver machine perfusion (NLMP) compared to the traditional method of static cold storage (SCS). Out of 332 liver transplants performed, 174 used NLMP, and one-year survival rates of the transplanted organs were 81.3% for NLMP and 83.8% for SCS, showing that NLMP can perform just as well, while also allowing for longer preservation times and more daytime surgeries. The findings suggest that using NLMP could improve the logistics of liver transplants without harming patient outcomes. Who this helps: This helps both patients needing liver transplants and the medical teams performing them.

Plain English
This study looked at the effects of a medication called glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver health in people with type 2 diabetes. Researchers found that using GLP-1RAs was linked to a 29% lower risk of serious liver problems and a 30% lower risk of liver failure compared to other diabetes medications. This is important because it shows that GLP-1RAs can help protect the liver, not just improve blood sugar levels. Who this helps: Patients with type 2 diabetes, especially those at risk of liver complications.

Plain English
This paper studied how metabolic dysfunction-associated steatotic liver disease (MASLD) affects the risk of serious infections that require hospital treatment. Researchers found that people with MASLD, especially those with advanced liver disease like cirrhosis, have a higher chance of developing serious bacterial infections, and this risk is further amplified in cases of severe viral infections such as COVID-19. Understanding these risks is important because it helps identify patients who may need closer monitoring and treatment to prevent severe infections. Who this helps: This helps patients with MASLD and their healthcare providers.

Plain English
This study looked at how immune cells interact in the livers of children suffering from a severe liver condition called acute hepatitis of unknown origin (AHUO). They found that most of the patients had evidence of past COVID-19 infections, with significant immune cell activity observed in the liver, particularly a type of immune cell called CD8 T-cells, which were linked to more severe liver damage. Importantly, these findings suggest that the effects of COVID-19 might contribute to liver issues in children, making it essential to test for COVID-19 in these cases. Who this helps: This helps patients, especially children with liver conditions, and their doctors in diagnosing and treating hepatitis related to past COVID-19 infections.

Plain English
This study looked at how a specific genetic variant (rs12979860) affects inflammation in critically ill COVID-19 patients. Researchers found that patients with the TT genetic variant had a higher peak of inflammation markers, needed kidney treatments more often (31.6% versus 11.7%), and required longer mechanical ventilation (22 days versus 15 days) compared to other genetic groups. Understanding these genetic differences helps predict how severely patients may react to COVID-19 and what treatments they may need. Who this helps: This helps doctors better treat critically ill COVID-19 patients by identifying those at higher risk for severe inflammation.

Plain English
This study looked at how taking sodium-glucose cotransporter 2 (SGLT2) inhibitors affects the likelihood of serious liver issues in people with type 2 diabetes. Researchers analyzed data from over 626,000 patients and found that those using SGLT2 inhibitors had a 17% lower risk of major liver problems and a 36% lower risk of liver-related deaths compared to those using other diabetes medications. This is important because it suggests that SGLT2 inhibitors may not only help manage blood sugar levels but also protect against severe liver complications. Who this helps: This benefits patients with type 2 diabetes and their healthcare providers.

Plain English
This study examined the long-term effects of a drug called obefazimod in patients with moderate-to-severe ulcerative colitis (UC) over 96 weeks. The results showed that 73% of patients responded well to the treatment by the end of the study, and about 53% achieved clinical remission. Safety monitoring showed that while 68% of patients reported some side effects, most were mild, with no new safety issues identified. Who this helps: This benefits patients suffering from moderate-to-severe ulcerative colitis looking for effective treatment options.

Plain English
This study examined how a family history of diabetes affects the health outcomes of individuals with type 2 diabetes. It found that people with a family history were diagnosed at a younger age and had a 41% higher risk of developing neuropathy, but a 16% lower risk of heart and blood vessel diseases compared to those without a family history. This information is important because it highlights the different health risks faced by diabetic patients depending on their family background, especially in men who showed a higher risk for heart-related issues. Who this helps: This helps patients with type 2 diabetes and their healthcare providers.

Plain English
This study looked at the effectiveness of a type of medication called glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating liver diseases linked to fat buildup, specifically metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). The results showed that GLP-1RAs, particularly semaglutide at a dose of 2.4 mg per week, helped achieve resolution of MASH in patients with moderate to severe liver damage and improved liver fibrosis. In terms of numbers, patients taking GLP-1RAs were 3.48 times more likely to see MASH resolution and had a 1.79 times better chance of improved fibrosis compared to those on a placebo. Who this helps: This benefits patients with MASH and moderate to advanced liver fibrosis.

Plain English
This study looked at two liver disorders called MASLD and MASH, which are caused by too much fat buildup in the liver. Researchers found that people with these conditions had lower levels of a protein called G3BP1, and when they tested mice that lacked this protein, those mice showed worse liver problems and more fat buildup. This discovery is important because it highlights G3BP1’s role in liver health and suggests it could be a target for new treatments. Who this helps: This helps patients with liver diseases like MASLD and MASH.

Plain English
This study looked at how a protein called ACBP in the liver relates to weight loss after bariatric surgery, which helps people with severe obesity. Researchers found that ACBP levels in the blood increased significantly after surgery, and higher levels of ACBP before surgery were linked to greater weight loss six months later. Understanding ACBP’s role might help doctors identify who will benefit most from this type of surgery in the future. Who this helps: Patients considering bariatric surgery.

Plain English
This study focused on improving how doctors assess liver tumors called hepatocellular carcinoma (HCC) using a method called LI-RADS. Researchers compared traditional visual evaluations with a software tool that automatically analyzes these tumors. They found that the software agreed with human assessments 98% of the time for certain characteristics, making it a reliable option for HCC classification. Who this helps: This helps doctors and researchers working with liver cancer patients.

Plain English
This study focuses on how to manage a liver condition called metabolic dysfunction-associated steatotic liver disease (MASLD), which is often linked to issues like obesity and diabetes. Experts from various Austrian medical societies have come together to offer practical advice for treating patients with this condition, especially when it overlaps with alcohol-related liver disease. Their recommendations aim to improve care for these patients, as effective management is crucial for preventing serious health problems. Who this helps: This benefits patients dealing with liver disease, especially those with metabolic disorders and alcohol-related issues.

Plain English
This study looked at the effects of low red blood cell counts (anemia) and blood transfusions on survival for patients undergoing colorectal cancer surgery. Out of 654 patients analyzed, 62.4% had anemia, and those who received blood transfusions had lower survival rates after one year compared to those who did not; specifically, 30.3% of patients had transfusions, but these did not improve survival. The results highlight the need for managing anemia before surgery to help better outcomes after the procedure. Who this helps: This helps patients undergoing colorectal cancer surgery.

Plain English
This study looked at how certain substances called adipokines, released by fat tissue, influence the body's immune responses in obesity, leading to conditions like insulin resistance and liver disease. The findings show that in both mice and humans, adipokines play a significant role in creating metabolic inflammation, which can lead to serious health problems. Understanding these mechanisms can help develop new treatments for obesity-related diseases. Who this helps: This benefits patients struggling with obesity and related metabolic disorders, as well as doctors seeking better treatment options.

Plain English
This paper studied how the research on microbiomes, which are the tiny organisms living in our bodies, can be used in medical practice. It found that while there is promising evidence for using microbiomes to help diagnose and treat diseases, such research is not yet part of standard medical care. The authors emphasize the need for better communication between researchers and doctors, as well as improvements in research methods. Who this helps: This benefits patients by potentially providing new ways to diagnose and treat their health issues.

Plain English
This study examined the connection between gut bacteria and atherosclerosis, a condition where arteries become inflamed and clogged, leading to heart problems. Researchers found that people with atherosclerosis often have imbalances in their gut bacteria, including an increase in certain harmful types. Some gut bacteria can contribute to inflammation and artery damage, while others might help protect against it. Understanding these relationships could lead to new treatments that target gut health to help fight heart disease. Who this helps: This research benefits patients at risk for heart disease and stroke.

Plain English
This study focused on the growing interest in using gut microbiome tests in healthcare but found that current evidence for their effectiveness is lacking. An expert panel was formed to create guidelines for how these tests should be used to ensure that they are reliable, safe, and valuable in a clinical setting. Their goal is to avoid wasting resources on tests that don’t help patients and to improve the overall quality of healthcare involving microbiome diagnostics. Who this helps: This helps patients and healthcare providers by ensuring that microbiome tests are effective and properly regulated.

Plain English
This study looked at fecal microbiota transplantation (FMT) as a treatment for ulcerative colitis, a type of inflammatory bowel disease. Experts found that while FMT has shown promise in helping patients with this condition, there is still a need for more thorough clinical trials to properly assess its effectiveness. They highlighted the importance of creating standardized methods for future studies, which could lead to better treatment options and improved health outcomes for patients. Who this helps: This helps patients with ulcerative colitis seeking new treatment options.

Plain English
This study looked at the links between inflammatory bowel diseases (IBD) and metabolic disorders, highlighting that both are increasingly common due to modern lifestyle changes and diets. The research found that patients with IBD often experience metabolic disorders, which can worsen their overall health and lead to more complications. Addressing obesity not only helps with metabolic health but can also improve outcomes for those with IBD. Who this helps: Patients with inflammatory bowel diseases and healthcare providers.

Plain English
This study looked at how primary hypothyroidism, a condition where the thyroid doesn't produce enough hormones, is linked to metabolic dysfunction-associated steatotic liver disease (MASLD), a type of fatty liver disease. Researchers analyzed data from over 76 million people and found that those with hypothyroidism had a 43% higher chance of having MASLD, and an even greater 184% higher risk of severe liver damage. These findings highlight the importance of monitoring liver health in patients with hypothyroidism to prevent serious complications. Who this helps: This helps patients with hypothyroidism, doctors treating them, and healthcare providers involved in liver disease management.

Plain English
This study looked at how oxidative stress (a harmful imbalance between free radicals and antioxidants) affects liver function after surgeries that remove part of the liver. Among the 52 patients involved, 25% experienced post-hepatectomy liver failure (PHLF), which significantly raised their risk of dying within 90 days of surgery (23% who had PHLF died compared to 0% of those who did not). The findings highlight that monitoring specific stress markers during and after surgery can help predict who is at risk for serious liver problems, particularly in patients with advanced cholangiocarcinoma (bile duct cancer). Who this helps: This helps patients undergoing liver surgery and their doctors by identifying risk factors for severe complications.

Plain English
This paper corrects previous information about the role of transplants in treating cancer. It clarifies current practices and new strategies in transplant oncology, which have the potential to improve outcomes for many patients. This work is important because it helps ensure that cancer patients receive the best possible treatment options based on the latest findings. Who this helps: This helps patients with cancer and their doctors.

Plain English
This study looks at how the Western-style diet, which is high in processed foods and low in nutrients, is connected to various chronic diseases like heart problems, obesity, and diabetes. It emphasizes that this dietary trend is making people more vulnerable to health issues, leading to serious conditions like cardiovascular disease and liver problems. The findings urge healthcare providers and society to take immediate action to reduce the negative impacts of this diet on health. Who this helps: This helps patients at risk of chronic diseases, doctors, and public health officials.

Plain English
This research looked at how common metabolic diseases like type 2 diabetes, high blood pressure, obesity, high cholesterol, and liver disease have affected global health from 1990 to 2021. It found that high blood pressure was the biggest problem, causing 226 million years of healthy life lost, while type 2 diabetes led to 75 million years of disability. Over these years, the overall burden of these diseases has grown significantly, with diabetes and obesity increasing at the fastest rates, highlighting the urgent need for global health efforts to combat these conditions. Who this helps: This benefits patients suffering from metabolic diseases and healthcare providers seeking to improve health outcomes.

Plain English
This study looked at the differences between two types of fatty liver disease: nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD). It found that people with MAFLD had a 12% higher overall risk of dying and a 15% higher risk of dying from heart-related issues compared to those with NAFLD. Understanding these differences is important because it helps identify patients at greater risk for serious health problems. Who this helps: This helps patients and doctors better assess risks related to fatty liver disease.

Plain English
This study looks at what makes a gut microbiome healthy and acknowledges that changes in gut bacteria can affect chronic diseases and treatment effectiveness. The authors find it challenging to define a healthy microbiome because factors like diet, lifestyle, and individual differences play a significant role; they emphasize that there's no single definition for gut health. Understanding these complexities is essential for improving health treatments and outcomes. Who this helps: This benefits patients, healthcare providers, and researchers studying gut health and disease connections.

Plain English
This study examined the impact of a fast vaccination campaign against COVID-19 in Schwaz, Austria, where 66.9% of eligible residents received the BNT162b2 vaccine. Over two years, there were 1,672 confirmed COVID-19 cases among the participants, with the vaccine reducing infections by 81.6% in the first 9 months, dropping to 38.2% in the following 10-24 months. This is important because it shows that a rapid vaccination rollout can significantly lower COVID-19 cases, especially in the early months, and encourages more people to get booster shots. Who this helps: This helps patients by reducing their risk of COVID-19 infection and supporting public health efforts.

Plain English
This study looked at how the gut and its connections to the brain might play a role in Long COVID, the range of symptoms that some people experience after recovering from COVID-19. It found that changes in gut bacteria, damage to the gut lining, and lingering virus particles in the digestive system could lead to ongoing issues like inflammation and mental health problems. Understanding these connections is crucial for developing better ways to diagnose and treat Long COVID. Who this helps: This research benefits patients suffering from Long COVID and their healthcare providers.